Burning Rock Biotech Limited is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in Guangzhou, Guangdong, CN. Its filings are on EDGAR under CIK 1792267; the figures the desk reads are not on file yet.
Usage businessServices-Medical LaboratoriesGuangzhou, Guangdong, CNfilings since 20197 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.2 out of ten, 7 of 9 metrics filed and 2 estimated: past 5.3 out of ten, present 5.1 out of ten, future 5.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 7.8 out of ten. No warning events in its filings since 2019. 78th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.1 out of ten. +14.5% a year over 8 filed years; profitable in 0 of 8. 32nd percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.8 out of ten. CrossAssetData estimate 5.8/10, confidence 20 of 100 (family median). 50th percentile among 20 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Financial health (present): 6.7 out of ten. ROE -10%: lost 10¢ per shareholder dollar. Leverage 35%: owes 35¢ per asset dollar. 67th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.5 out of ten. bottom 35% of 23 in its family; net margin -10.3%. 35th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 6.0 out of ten. CrossAssetData estimate 6.0/10, confidence 20 of 100 (family median). 50th percentile among 20 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 7.4 out of ten. top 26% of 23 in its family for room to expand. 74th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 1.8 out of ten. bottom 18% of 23 in its family for growth drivers. 18th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.4 out of ten. top 16% of 20 in its family for expectations against reality. 84th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-04-28 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-10. Filings on record since 2019. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Inhospital Business 42%, Central Laboratory Business 30%, Pharma Research and Development Services 29%. As tagged in its annual report (Form 20-F, filed 2026-04-28).
Who runs it
Hu, Xiaozhi (Senior Director in Finance); Han, Yusheng (director); Deng, Feng (director); Hayes, Wendy W. (director); Xu, Licen Lisa (director); Zhang, Zhihong (director). 6 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.